Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
JOURNALS
PSYCHOPHARMACOLOGY BULLETIN
FULL ISSUE STACKED PDFs
T.E.N.
MENTAL FITNESS
PSI
ONCOLOGY SPECTRUMS
PROJECTS
JOURNAL SUPPLEMENTS
PHYSICIAN ACADEMY SERIES
POCKET REFERENCE GUIDES
TEACHING MONOGRAPHS
MEDWORKS REPRINT SERIES
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOTROPIC PRESCRIBING INFORMATION
PSYCHOTROPIC DOSAGE RANGES
PSYCHOPHARMACOLOGY 101
PSYCHIATRIC RATING SCALES
NEWS
WE KNOW PSYCHIATRY
FEATURED ARTICLES
Home
michael-e-thase
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry
$
0.00
Add to cart
Details
Psychopharmacology Bulletin VOL 36 Supplement No. 3 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Psychopharmacology Bulletin VOL 36 Supplement No. 2 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Psychopharmacology Bulletin VOL 36 Supplement No. 1 – Full Issue Stacked PDF
$
0.00
Add to cart
Details
Sale!
VOL 3 No. 8 Full Issue – August 2001
$
30.00
$
20.00
Add to cart
Details
Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
$
30.00
Add to cart
Details
Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression
$
30.00
Add to cart
Details
Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study
$
30.00
Add to cart
Details
Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia)
$
30.00
Add to cart
Details
The Ham-D is not Hamilton’s Depression Scale + Commentary on the Hamilton Rating Scale for Depression by Leon I. Rosenberg & Michael E. Thase
$
30.00
Add to cart
Details
Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies
$
30.00
Add to cart
Details
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide
$
30.00
Add to cart
Details
Previous
1
2
Page load link
Go to Top
